Fortress Biotech's stock was trading at $1.61 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. FBIO stock was acquired by a variety of institutional investors in the last quarter, including Diversified Trust Co. Company insiders that have bought Fortress Biotech stock in the last two years include Lindsay A Md Rosenwald, Malcolm Hoenlein, and Robyn Hunter. Most stock quote data provided by BATS. All rights reserved.
Dow Jones: The Dow Jones branded indices are proprietary to and are calculated, distributed and marketed by DJI Opco, a subsidiary of S&P Dow Jones Indices LLC and have been licensed for use to S&P Opco, LLC and CNN. Fundamental company data provided by Morningstar and Zacks Investment Research. Sign-up to receive the latest news and ratings for FBIO and its competitors with MarketBeat's FREE daily newsletter. The biopharmaceutical company reported ($0.19) earnings per share for the quarter, topping analysts' consensus estimates of ($0.27) by $0.08. Fortress Biotech employs 93 workers across the globe.
As of September 15th, there was short interest totaling 2,030,000 shares, an increase of 48.2% from the August 31st total of 1,370,000 shares. Στοιχεία ελέγχου του ιδιωτικού απορρήτου σας, Πληροφορίες σχετικά με τη συσκευή σας και τη σύνδεσή σας στο διαδίκτυο, συμπεριλαμβανομένης της διεύθυνσης IP, Δραστηριότητα περιήγησης και αναζήτησης κατά τη χρήση των ιστότοπων και των εφαρμογών της Verizon Media. Learn about financial terms, types of investments, trading strategies and more. ), Fortress Biotech has received 263 “underperform” votes. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. All rights reserved. View institutional ownership trends for Fortress Biotech. See what's happening in the market right now with MarketBeat's real-time news feed.
Export data to Excel for your own analysis. Identify stocks that meet your criteria using seven unique stock screeners. © 2020 Cable News Network. View insider buying and selling activity for Fortress Biotech. Post-Market 0.04 (1.49%) Based on an average trading volume of 1,450,000 shares, the short-interest ratio is presently 1.4 days. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock.
Fortress Biotech has received a consensus rating of Buy.
According to analysts' consensus price target of $7.55, Fortress Biotech has a forecasted upside of 189.3% from its current price of $2.61. You may vote once every thirty days. Fortress Biotech, Inc. was founded in 2006 and is based in New York, New York. MarketBeat's community ratings are surveys of what our community members think about Fortress Biotech and other stocks.
View our full suite of financial calendars and market data tables, all for free. Fortress Biotech, Inc. (FBIO) - 4 - Statement of Changes in Beneficial Ownership SEC Filings Tue, Sep. 01 Fortress Biotech, Inc. (FBIO) - 424B5 - Prospectus filed pursuant to Rule 424(b)(5) Earnings for Fortress Biotech are expected to grow in the coming year, from ($0.93) to ($0.51) per share. The company has collaboration arrangements with some universities, research institutes, and pharmaceutical companies. CNN Sans™ & © 2016 Cable News Network. View all competitors. Morningstar: © 2019 Morningstar, Inc. All Rights Reserved. Vote “Outperform” if you believe FBIO will outperform the S&P 500 over the long term. (Add your “outperform” vote. Get daily stock ideas top-performing Wall Street analysts. On average, they expect Fortress Biotech's share price to reach $7.55 in the next year. Specifically, they have bought $1,245,006.00 in company stock and sold $124,611.00 in company stock. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." Fortress Biotech has received 52.95% “outperform” votes from our community. View insider buying and selling activity for Fortress Biotech. Fortress Biotech (NASDAQ:FBIO) issued its quarterly earnings results on Monday, August, 10th. Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter. Fortress Biotech has received 296 “outperform” votes. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.